Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
266,941,931
-
Total 13F shares
-
84,238,825
-
Share change
-
-2,294,213
-
Total reported value
-
$532,433,824
-
Put/Call ratio
-
194%
-
Price per share
-
$6.32
-
Number of holders
-
147
-
Value change
-
-$9,578,644
-
Number of buys
-
67
-
Number of sells
-
60
Institutional Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q4 2019
As of 31 Dec 2019,
Akebia Therapeutics, Inc. - Common Stock (AKBA) was held by
147 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
84,238,825 shares.
The largest 10 holders included
BAUPOST GROUP LLC/MA, BlackRock Inc., Nantahala Capital Management, LLC, ABRAMS CAPITAL MANAGEMENT, L.P., VANGUARD GROUP INC, STATE STREET CORP, Novo Holdings A/S, Point72 Asset Management, L.P., Nuveen Asset Management, LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
147
institutional shareholders reporting positions in this security
for the Q4 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.